MedTrace Logo

Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer

NCT02733250 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-02-16

No results posted yet for this study

Summary

The purpose of this study is to determine the optimal dose of nab-paclitaxel to be safely administered in combination with pembrolizumab in patients with advanced inoperable non-small cell lung cancer. The study is also aimed at evaluating the efficacy of the combination therapy.

Conditions

Interventions

BIOLOGICAL

Pembrolizumab

200mg IV Day 1 of each 21 cycles

DRUG

Nab-Paclitaxel

100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles

Sponsors & Collaborators

  • Centre de Recherche du Centre Hospitalier de l'Université de Montréal

    collaborator OTHER

  • Merck Canada Inc.

    collaborator INDUSTRY

  • Celgene

    collaborator INDUSTRY

  • Jewish General Hospital

    collaborator OTHER

  • Centre hospitalier de l'Université de Montréal (CHUM)

    lead OTHER

Principal Investigators

  • Normand Blais, MD · Centre hospitalier de l'Université de Montréal (CHUM)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-13
Primary Completion
2019-04-13
Completion
2019-12-13

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02733250 on ClinicalTrials.gov